Merck Sees $1.23 Million Bullish Call Activity as Stock Hovers Near 52-Week Highs

By TrendSpider Editor

A notable options contract crossed the tape for Merck & Company, Inc. (MRK) on Monday, September 28, 2026, with a single call position commanding $1,231,000 in premium at the $145 strike. The trade arrives with MRK shares trading at $148.46, down just 0.24% on the session, and sitting meaningfully c

Merck Sees $1.23 Million Bullish Call Activity as Stock Hovers Near 52-Week Highs

A notable options contract crossed the tape for Merck & Company, Inc. (MRK) on Monday, September 28, 2026, with a single call position commanding $1,231,000 in premium at the $145 strike. The trade arrives with MRK shares trading at $148.46, down just 0.24% on the session, and sitting meaningfully closer to the top of its 52-week range of $77.58 to $156.92 than its bottom. The in-the-money positioning of the contract adds an additional layer of conviction to the activity.

Key Drivers of the MRK Stock Move

• Main Catalyst: One unusual call contract was flagged at the $145 strike expiring January 15, 2027, carrying $1,231,000 in premium and printing with open interest utilization of 34%. The contract is currently in the money with MRK trading at $148.46.
• Bull Case: The call is in the money, suggesting the buyer has immediate intrinsic value working in their favor. With the stock trading near $148.46 and just $8.46 below the 52-week high of $156.92, a continued upward move would add further intrinsic value to the position before the January 2027 expiration.
• Bear Case: The 34% open interest utilization rate suggests this strike has seen prior activity, and MRK has already rallied substantially off its 52-week low of $77.58. A stock that has nearly doubled from its annual trough carries elevated reversion risk, and today's modest 0.24% decline could reflect early exhaustion near the top of its range.

The forward setup for MRK looks constructive based purely on options positioning. A January 2027 expiration gives the trader approximately 3.5 months for the thesis to play out, which spans a window that typically includes a quarterly earnings release and potential pipeline updates from Merck. The $1.23 million in premium deployed signals meaningful commitment rather than a speculative flier. That said, with the stock already deep into the upper half of its 52-week range, the risk-reward calculus depends heavily on whether Merck can sustain momentum and deliver on expectations through year-end and into early 2027.

MRK Unusual Options Activity

• Type: Call | Strike: $145 | Expiry: January 15, 2027 | Volume (Size): 1,000 contracts | Open Interest Utilization: 34% | Status: In the Money

Only one unusual contract was flagged in today's session, with all of the $1,231,000 in total premium concentrated in this single call position. The lack of any put activity reinforces the directionally bullish nature of the flow.

MRK Seasonality

Late September historically marks the transition into Q4, a period that has often been favorable for large-cap pharmaceutical names as year-end portfolio positioning and healthcare sector rotations gain momentum. A January 2027 expiration aligns the trade with what is traditionally a seasonally active stretch for biotech and pharma catalysts, including investor conferences and data readouts that typically cluster in the first quarter.

MRK Relative Performance

With MRK at $148.46 and trading within roughly 5.4% of its 52-week high of $156.92, the stock is exhibiting relative strength compared to where it stood near its annual low of $77.58. Today's marginal 0.24% pullback is not materially significant on a standalone basis and does not disrupt the broader bullish technical positioning implied by the options activity. The stock's proximity to 52-week highs suggests it has been outperforming on a longer-term basis relative to broader market volatility.